Key player in Pershing Square's Valeant bet leaving firm
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- S&P 500, Nasdaq rise with chips boost; Iran and megacap earnings in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- S&P 500, Nasdaq rise with chips boost; Iran and megacap earnings in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
Valeant (VRX) Derm NRx Up 1% Week-Over-Week, ophth NRx Down 5.1% - RBC
May 13, 2016 12:48 PM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 1.0% WoW, ophth NRx were down 5.1% WoW, and Addyi NRx were down 3.6% WoW.
Miehm commented, "For the week ending May 6th, new derm scripts (NRx) were up 1.0% vs. up 2.2% the prior... More
